188829-39-2

Basic information

• Product Name: whi-p131hydrochloride dihydrate
• Synonyms: 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline hydrochloride dihydrate;whi-p131hydrochloride dihydrate;JANEX-1, 4-(4μ-Hydroxylphenyl)-amino-6,7-dimethoxyquinazoline hydrate hydrochloride;WHI-P131 hydrate hydrochloride;4-(4′-Hydroxylphenyl)-amino-6,7-dimethoxyquinazoline hydrochloride hydrate;WHI-P131 hydrochloride hydrate
• CAS NO: 188829-39-2
• Molecular Formula: C16H16ClN3O3
• Molecular Weight: 333.76954
• Mol File: 188829-39-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: whi-p131hydrochloride dihydrate(CAS DataBase Reference)
• NIST Chemistry Reference: whi-p131hydrochloride dihydrate(188829-39-2)
• EPA Substance Registry System: whi-p131hydrochloride dihydrate(188829-39-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 188829-39-2(Hazardous Substances Data)

Upstream product

• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 20323-74-4 2-carboethoxy-4,5-dimethoxyaniline 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 
• 3943-77-9 ethyl veratrate 
• 93-07-2 Veratric acid 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 123-30-8 4-amino-phenol 
• 13790-39-1 6,7-dimethoxy-4-chloroquinazoline 

Relevant articles and documents

Model 18 F mark substituted [...] compound and its preparation method and tumor PET imaging applications

The invention provides a novel F marked substituted quinazoline compound. The novel F marked substituted quinazoline compound is characterized in that one end of the novel F marked substituted quinazoline compound has a F substituted alkyloxy structure; the other end of the compound has a 6,7-substituted quinazoline structure, and a substituent R1 is positioned in the 4 position of a quinazoline maternal, and is a 2-, 3-, 4-F substituted alkyloxy group; and a substituent R2 is positioned in the 6 position of the quinazoline maternal, and is a methoxyethoxy group, a methoxy group, or a morpholinepropanolato group. The structural formula of the compound is shown as A in the specification. Results of experiments show that the compound has the advantages of good bioactivity, good serum stability, low intake in tissues of the liver and the like, and high enrichment and slow removal rate in tumors, and the marking precursor of the compound has the advantages of easy synthesis, extremely high marking rate and the like, so the compound has a huge potential for the tumor PET development.

Quinazoline compounds and pharmaceutical compositions containing them

The use of a compound of formula (I) or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, NH or NR8 where R8 is hydrogen or C1-6alkyl; Ra is a 3-quinoline group or a group of sub-formula (i) where R5, R6 and R7 are various specific organic groups, in the preparation of a medicament for use in the inhibtion of aurora 2 kinase. Novel compounds of formula (I) and pharmaceutical compositions useful in the treatment of cancer are also described and claimed.